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Summary
Background There are numerous evidences suggesting that parathyroid hormone (PTH) plays a role in the patho-
genesis of arterial hypertension. Treatment with cinacalcet decreases serum PTH concentration in haemodialysed 
patients with chronic kidney disease (HDP) and secondary hyperparathyroidism (sHPT) Chronic kidney disease 
is a pro-inflammatory state. The aim of this study was therefore to assess the influence of 6-month treatment with 
cinacalcet on blood pressure (BP) and inflammation markers in HDP with sHPT. 
Material and methods In 58 HDP with sHPT serum PTH, interleukin-6, C-reactive protein, calcium and phos-
phate concentrations were assessed before the first dose of cinacalcet and after 3 and 6 months of treatment. BP was 
measured before haemodialysis sessions. 
Results Serum PTH concentration decreased significantly after 3 and 6 months of cinacalcet treatment from 1138 
(931–1345) to 772 (551–992); p<0.0001 and to 635 (430–839) pg/ml; p<0.0001, respectively. Systolic BP de-
creased after 3 and 6 months of treatment from 128 (123–133), to 125 (120–131) and to 121 (115–127) mm Hg, 
respectively (p for trend = 0.014). Diastolic BP did not change significantly. There were no significant differences in 
the number of antihypertensive drugs, vitamin D analogues dose and patients’ body weight, nor the serum concen-
trations of IL-6 and CRP during the treatment period. 
Conclusions 1. Six-month treatment with cinacalcet decreases systolic BP in haemodialysed patients with chronic 
kidney disease and secondary hyperparathyroidism. 2. The elucidation of exact pathomechanism of such a BP de-
crease needs further clinical studies, but it seems not to be related to inflammatory status changes.
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Background
Secondary hyperparathyroidism (sHPT) is among 
the most common abnormalities in haemodialysed 
patients with chronic kidney disease (CKD). The ae-
tiopathogenesis of sHPT in CKD patients is complex 
and still not fully understood. Nevertheless, it can be 
generally summed up as the excessive parathormone 
(PTH) secretion caused by hyperphosphataemia, hy-
pocalcaemia and low vitamin D status [1, 2]. 
PTH is regarded as one of the uraemic toxins and 
is one of the factors contributing to the pathogenesis 
of hypertension, which was documented in experi-
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mental studies [3], as well as in clinical studies con-
ducted among others in maintenance haemodialysis 
(HD) patients [4, 5]. Moreover PTH seems to be 
associated with the increased cardiovascular burden 
in HD patients, in earlier stages of CKD as well as in 
general population [6–10]. 
Cinacalcet is a type II calcimimetic. Such com-
pounds bind to the calcium receptor (CaR), which 
results in its increased sensitivity to serum calcium. 
This leads to the decrease of parathormone (PTH) 
production by the parathyroid glands [11, 12]. Ci-
nacalcet is now commonly used in the treatment 
of secondary hyperparathyroidism in haemodialysed 
CKD patients. In the ACHIEVE study combined ci-
nacalcet and small dose vitamin D treatment showed 
greater reduction in the progression of vascular and 
heart valve calcification compared to vitamin D 
alone [13–15].
Multiple lines of evidence suggest that PTH may 
be involved in the pathogenesis of hypertension. It 
has been shown that the excess serum PTH concen-
tration in uraemia leads to the increase of calcium 
content in many cells and tissues (among them in 
blood vessels [16] and heart [17]). Results of animal 
experiments suggest that parathyroidectomy in 5/6 
nephrectomised rats improved the endothelial dys-
function (normalized the synthesis of nitric oxide 
by the endothelial cells) [18]. Similar results were 
obtained from the clinical studies. Serum PTH con-
centration was found to be an independent predictor 
of the new-onset hypertension [19], as well as the left 
ventricle hypertrophy [20]. Moreover, parathyroidec-
tomy causes the blood pressure decrease in patients 
with primary hyperparathyroidism [22].
It is well known that chronic kidney disease is 
a pro-inflammatory state. The results of recent stud-
ies have shown that the serum concentrations of 
markers of inflammation are significantly elevated 
in CKD patients [23–25]. Moreover, it was found 
that the extent of inflammation (measured by the 
neopterin concentration) is inversely related to the 
eGFR [26].
It has been shown that circulating PTH may stim-
ulate the secretion of IL-6 in osteoblasts. This may be 
the cause of the elevated serum IL-6 concentration in 
secondary as well as in primary hyperparathyroidism. 
IL-6 is one of the main stimulants of the elevated 
synthesis of the so called acute phase proteins (e.g. 
CRP and fibrinogen) in the liver [27–29]. 
Taking into consideration the fact that PTH sub-
stantially contributes to the development of hyper-
tension, it was reasonable to study the influence 
of 6-month cinacalcet treatment on blood pressure 
in haemodialysed patients with CKD and sHPT. 
Moreover, since PTH may induce IL-6 synthesis and 
cinacalcet reduces serum PTH concentration and 
taking into account the contribution of the inflam-
matory status in the pathogenesis of hypertension 
[32], it was interesting to assess the influence of 
cinacalcet on the blood pressure in in these patients.
Materials and methods
Seventy-one adult, haemodialysed CKD patients (40 
males, 31 females) with sHPT (defined as serum PTH 
concentration > 300 pg/ml) recruited from 9 different 
haemodialysis centres were enrolled in this clinical, 
prospective, open-label, single-arm study. Mean age 
of patients was 53.3 ± 14.8 years, median time of re-
nal replacement therapy was 32 months [interquartile 
range (IQR) — 28 months]. Exclusion criteria were: 
age below 18 years, severe liver insufficiency, over-
sensitivity to any of the study drug compounds, high 
probability of non-compliance and suspected short life 
expectancy on renal replacement therapy. 
Patients were treated with cinacalcet. Initial dose 
was 30 mg once daily and was modified, if needed, 
every 4 weeks depending on the serum PTH con-
centration. The target of treatment was to decrease 
serum PTH concentration to 150–300 pg/ml. Maxi-
mal dose of cinacalcet was 120 mg daily.
The doses of calcium carbonate and vitamin D 
analogues were flexible in order to avoid cinacalcet 
related hypocalcaemia and hypophosphataemia. Alu-
minium hydroxide was only used as a temporary 
“rescue” therapy in patients with severe hyperphos-
phataemia.
In every patient, plasma serum PTH (electroche-
miluminescence; Roche, Mannheim, Germany), in-
terleukin-6 (ELISA; R&D Systems, Abingdon, UK), 
C-reactive protein (ELISA; Immunodiagnostic AG, 
Bensheim, Germany), calcium and phosphate (Beck-
man Coulter UniCel DXC 600 analyser) concentra-
tions were assessed before the first dose of cinacalcet 
and then after 3 and 6 months of treatment. Blood 
samples were collected before haemodialysis proce-
dure in the middle of the week. After collection, 
blood samples were centrifuged, serum was aliquoted 
in 1ml test-tubes and then rapidly frozen in –70oC.
Moreover, in each patient arterial blood pressure 
was assessed on the brachial artery. The measurement 
was conducted before three consecutive haemodia-
lysis sessions preceding the blood samples collection. 
Statistical analyses were performed using the Sta-
tistica 10.0 PL software (StatSoft Polska, Cracow, 
Poland). Shapiro-Wilk test was used to test the vari-
ables distribution. Repeated measures ANOVA with 
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Bonferroni’s correction for multiple comparisons, or 
alternatively Wilcoxon matched pairs test were used 
to assess the longitudinal changes of variables. Cor-
relation coefficients were calculated using Spearman’s 
rank correlation. 
Results are shown as means with 95% confidence 
interval (CI), or as means with standard deviation, 
alternatively as median values with interquartile range 
(IQR) for variables with skewed distribution. Differ-
ences were considered significant when p < 0.05. The 
study protocol, adherent to Declaration of Helsinki, 
was approved by the Medical University of Silesia 
Bioethics Committee (KNW/0022/KB1/56/I/10 — 
21.09.2010) and all patients gave their written in-
formed consent for participation in the study. 
Results
From 71 enrolled patients, 58 (35 males, 23 females, 
mean age 53.8 ± 14.9 years) completed the study. Thir-
teen patients were ruled out of the study; among them 
4 people died, 2 received kidney allograft, 2 patients 
discontinued the study because of permanent de-
crease of serum PTH concentration below 150 pg/ml, 
2 underwent parathyroidectomy, one patient refused 
to continue the study due to paraesthesia; one pa-
tient withdrew the consent for the study and one 
moved out of the Silesian province. 
The mean doses of cinacalcet after 3 and 6 months 
of treatment were 42 ± 17 mg and 51 ± 23 mg re-
spectively. The doses of intestinal phosphate binders 
and active vitamin D3 analogues were flexible in or-
der to avoid hypocalcaemia and hypophosphataemia 
related to cinacalcet treatment. The percentage of pa-
tients treated with vitamin D analogues (alfacalcidol) 
and mean daily dose of alfacalcidol increased from 
0.26 mg (0.17–0.36 mg) at the baseline, to 0.39 mg 
(0.25–0.52 mg); (p for trend = 0.04; Table 1). More-
over, there was a significant (p for trend = 0.01) 
decrease in the mean dose of aluminium hydroxide 
(Alusal) from 385 mg/day (170–410 mg/day) at the 
baseline, to 180 mg/day (15–350 mg/day) after 6 
months of treatment. The number of patients treated 
with aluminium hydroxide also decreased (Table 1). 
The mean dose of calcium carbonate and the number 
of patients treated with this drug remained stable 
(Table 1).
In patients who completed the study cinacalcet 
treatment caused significant decrease of serum PTH 
from 1138 pg/ml (931–1345 pg/ml) at the baseline, 
to 772 pg/ml (551–992 pg/ml) after 3 month of 
treatment, and to 635 pg/ml (430–839 pg/ml) after 
6 months of treatment (p for trend < 0.0001; Table 2). 
The mean decrease of serum PTH concentration 
after 3 and 6 months of treatment was 32.2% and 
44.2%, respectively.
Six months of treatment with cinacalcet was as-
sociated with a significant (p for trend = 0.014) 
reduction of the mean systolic blood pressure from 
128 mm Hg (122–133 mm Hg) at the baseline to 
125 mm Hg (120–131 mm Hg) after 3 months and 
123 mm Hg (118–128 mm Hg) after 6 months. 
There were no significant (p for trend = 0.14) dif-
ferences in the diastolic blood pressure: 76 mm Hg 
(73–79 mm Hg), 76 mm Hg (73–79 mm Hg) and 
75 mm Hg (71–77 mm Hg) — Figure 1.
In the entire study group there were no signif-
icant differences in the mean serum calcium and 
phosphate concentration during cinacalcet treatment 
Table 1. Doses of alfacalcidol, intestinal phosphate binders and the number of patients using those drugs during cinacalcet treatment
Before treatment After 3 months of 
treatment
After 6 months of 
treatment
p for trend
Dose of alfacalcidol
[mg/24h]
0.26
(0.17–0.36)
0.32
(0.2–0.44)
0.39*
(0.25–0.52)
0.04
Number of patients treated with alfacalcidol 30 (52%) 34 (59%) 40 (69%) 0.06
Dose of CaCO3
[g/24h]
3.49
(2.68–4.30)
3.84
(2.95–4.72)
3.88
(3.04–4.72)
0.053
Number of patients treated with CaCO3 53 (91%) 55 (95%) 54 (93%) 0.71
Dose of aluminium hydroxide
[mg/24h]
385
(170–605)
310
(80–540)
180*
(15–350)
0.01
Number of patients treated with aluminium hydroxide 12 (21%) 8 (14%) 5 (9%) 0.06
*p < 0.05 vs baseline (Bonferroni corrected)
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Table 2. The changes of serum parathormone, inflammation markers, calcium and phosphate concentrations during the treatment with 
cinacalcet 
Before treatment After 3 months of 
treatment
After 6 months of 
treatment
p for trend
PTH
[pg/ml]
1138
(931–1345)
772
(551–992)
635
(430–839)
< 0.0001
CRP
[mg/l]
11.2
(9.2–13.1)
11.6
(9.4–13.7)
10.5
(8.6–12.4)
0.54
IL-6
[pg/ml]
5.76
(4.77–6.75)
6.28
(5.11–7.45)
5.72
(4.76–6.68)
0.94
Ca
[mmol/l]
2.15
(2.07–2.22)
2.11
(2.04–2.17)
2.09
(2.01–2.16)
0.15
Phosphate
[mmol/l]
2.02
(1.87–2.18)
1.97
(1.80–2.14)
1.89
(1.73–2.05)
0.10
*p < 0.05 vs baseline (Bonferroni corrected)
PTH — parathormone; CRP — C-reactive protein; IL-6 — Interleukin 6; SBP — systolic blood pressure; DBP — diastolic blood pressure
Figure 1. The changes of blood pressure during 6 months of cina-
calcet treatment
(Table 2). Also, the mean serum concentrations 
of inflammation markers (CRP and IL-6) did not 
change significantly during the observation period. 
There were no significant correlations between 
the changes of serum concentrations of PTH and 
markers of inflammation, nor the changes of the 
aforementioned and the changes of blood pressure. 
Moreover there were no significant correlations be-
tween the changes of PTH, inflammation markers or 
blood pressure and the dose of alfacalcidol.
Discussion
In this multicentre prospective open-label single-arm 
clinical study a significant decrease of systolic blood 
pressure during the 6 months treatment with ci-
nacalcet was observed. There were no significant 
differences in the patients’ diastolic blood pressure.
Treatment with cinacalcet was not associated with 
any significant changes of the serum concentration 
of inflammation markers — the concentrations of 
both CRP and IL-6 remained stable during the ob-
servation period. 
Secondary hyperparathyroidism is characterized 
by, among others, the excess of PTH secretion and 
PTH is one of the factors contributing to the devel-
opment of hypertension in maintenance haemodi-
alysis patients [33], patients in pre-dialysis stages of 
CKD [34], as well as in general population [35, 36]. 
Nevertheless there’s only one paper published so 
far concerning the influence of cinacalcet on blood 
pressure in the maintenance haemodialysis pa-
tients. In the secondary analyses of the EVOLVE 
trial Chang et al. found that 20 weeks treatment 
with cinacalcet resulted in a 2.2 mm Hg decrease in 
systolic blood pressure and a 1.3 mm Hg decrease 
in diastolic blood pressure when compared with 
placebo. This is partly in agreement with the results 
of current study, as we found a 5 mm Hg decrease in 
the systolic blood pressure but no differences in the 
diastolic blood pressure after 6 months of treatment.
Similarly to the results of current and EVOLVE 
studies in patients after successful kidney transplan-
tation the reduction of BP caused by the cinacalcet 
treatment was described [21]. 
In the study by Bonet et al. [37] the authors 
found no significant differences in central and pe-
ripheral blood pressure under a 12-month cinacalcet 
regimen, but they did describe a significant reduc-
tion of pulse wave velocity (PWV) and a decrease of 
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left ventricle mass (borderline significance p = 0.06). 
The reduction of arterial stiffness and the decrease 
of the development of cardiovascular calcifications 
caused by the treatment with cinacalcet may be 
one of potential explanations of our findings, while 
the lack of differences in the central and peripheral 
blood pressure in the study by Bonet et al. might 
be, at least to a point, explained by the low number 
of enrolled participants. Also they assessed blood 
pressure in the day between dialysis procedures and 
we did the measurements directly before the HD 
session what may also contribute to the differences 
in the BP values.
Interestingly, there were no significant differences 
in PWV in patients on peritoneal dialysis treated 
with cinacalcet [38]. Nevertheless, the number of 
enrolled subjects was also low in this study (only 19) 
and cinacalcet failed to lower the serum PTH con-
centration in substantial number of these patients.
Another potential explanation of our findings 
may be the fact that CaR is expressed in the cells of 
juxtaglomerular apparatus in the kidney [39]. Ac-
tivation of CaR in these cells seems to decrease the 
plasma renin activity as it has been shown in both in 
vitro and in vivo studies [40, 31].
PTH stimulates the IL-6 synthesis and release. 
Elevated serum IL-6 contributes to the increase of 
CRP synthesis in the liver [27, 28]. We hypothe-
sized that treatment with cinacalcet may thus lower 
both IL-6 and CRP concentration through the 
decrease of serum PTH concentration. Moreover, 
parathyroidectomy was shown to decrease serum 
concentration of inflammation markers in patients 
with primary hyperparathyroidism [41, 42]. It is 
well known that systemic inflammation participates 
in the pathogenesis of hypertension. However, in 
the current study no significant changes in either 
IL-6, or CRP concentrations were found after 
6 months cinacalcet treatment. This is in agreement 
with the results published by Messa et al. In this 
study 6-month cinacalcet treatment didn’t cause any 
changes in serum IL-6 concentrations [43]. Also 
the overall IL-6 concentrations were similar those 
obtained in our patients. 
Our study has some unavoidable drawbacks. One 
is the lack of placebo treated control group. Anoth-
er one is the fact that we did not have data from 
ABPM measurements, but only from the clinical 
measurements, which may cause bias because of 
the intradialytic volume changes in maintenance 
haemodialysis patients. We recognize our study as 
a hypothesis generating one and hope to encourage 
the conduction of other clinical studies, hopefully 
with the use of ABPM. 
Conclusions
In conclusion, we found that six-month treatment 
with cinacalcet decreases systolic BP in haemodia-
lysed patients with chronic kidney disease and se-
condary hyperparathyroidism. The elucidation of 
exact pathomechanism of such a BP decrease needs 
further clinical studies, but it seems not to be related 
to inflammatory status changes. 
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